Medical Care
Global Next-Generation Gynecological Cancer Diagnostics Market Research Report 2025
- Mar 11, 25
- ID: 76837
- Pages: 85
- Figures: 89
- Views: 21
The global market for Next-Generation Gynecological Cancer Diagnostics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Next-Generation Gynecological Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next-Generation Gynecological Cancer Diagnostics.
The Next-Generation Gynecological Cancer Diagnostics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Next-Generation Gynecological Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Next-Generation Gynecological Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Quest Diagnostics Incorporated
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
Invitae Corporation
Konica Minolta, Inc.
BGI Genomics
CENTOGENE N.V.
Fulgent Genetics, Inc.
Illumina, Inc.
F. Hoffmann-La Roche Ltd
Laboratory Corporation of America Holdings
ARUP Laboratories
Myriad Genetics, Inc.
OPKO Health, Inc.
QIAGEN N.V.
Segment by Type
Ovarian Cancer Diagnosis
Cervical Cancer Diagnosis
Uterine Cancer Diagnosis
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Next-Generation Gynecological Cancer Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Next-Generation Gynecological Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next-Generation Gynecological Cancer Diagnostics.
The Next-Generation Gynecological Cancer Diagnostics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Next-Generation Gynecological Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Next-Generation Gynecological Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Quest Diagnostics Incorporated
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
Invitae Corporation
Konica Minolta, Inc.
BGI Genomics
CENTOGENE N.V.
Fulgent Genetics, Inc.
Illumina, Inc.
F. Hoffmann-La Roche Ltd
Laboratory Corporation of America Holdings
ARUP Laboratories
Myriad Genetics, Inc.
OPKO Health, Inc.
QIAGEN N.V.
Segment by Type
Ovarian Cancer Diagnosis
Cervical Cancer Diagnosis
Uterine Cancer Diagnosis
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Next-Generation Gynecological Cancer Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Ovarian Cancer Diagnosis
1.2.3 Cervical Cancer Diagnosis
1.2.4 Uterine Cancer Diagnosis
1.3 Market by Application
1.3.1 Global Next-Generation Gynecological Cancer Diagnostics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Next-Generation Gynecological Cancer Diagnostics Market Perspective (2020-2031)
2.2 Global Next-Generation Gynecological Cancer Diagnostics Growth Trends by Region
2.2.1 Global Next-Generation Gynecological Cancer Diagnostics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Next-Generation Gynecological Cancer Diagnostics Historic Market Size by Region (2020-2025)
2.2.3 Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Region (2026-2031)
2.3 Next-Generation Gynecological Cancer Diagnostics Market Dynamics
2.3.1 Next-Generation Gynecological Cancer Diagnostics Industry Trends
2.3.2 Next-Generation Gynecological Cancer Diagnostics Market Drivers
2.3.3 Next-Generation Gynecological Cancer Diagnostics Market Challenges
2.3.4 Next-Generation Gynecological Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Next-Generation Gynecological Cancer Diagnostics Players by Revenue
3.1.1 Global Top Next-Generation Gynecological Cancer Diagnostics Players by Revenue (2020-2025)
3.1.2 Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Players (2020-2025)
3.2 Global Next-Generation Gynecological Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Next-Generation Gynecological Cancer Diagnostics Revenue
3.4 Global Next-Generation Gynecological Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Next-Generation Gynecological Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next-Generation Gynecological Cancer Diagnostics Revenue in 2024
3.5 Global Key Players of Next-Generation Gynecological Cancer Diagnostics Head office and Area Served
3.6 Global Key Players of Next-Generation Gynecological Cancer Diagnostics, Product and Application
3.7 Global Key Players of Next-Generation Gynecological Cancer Diagnostics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Next-Generation Gynecological Cancer Diagnostics Breakdown Data by Type
4.1 Global Next-Generation Gynecological Cancer Diagnostics Historic Market Size by Type (2020-2025)
4.2 Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Type (2026-2031)
5 Next-Generation Gynecological Cancer Diagnostics Breakdown Data by Application
5.1 Global Next-Generation Gynecological Cancer Diagnostics Historic Market Size by Application (2020-2025)
5.2 Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Next-Generation Gynecological Cancer Diagnostics Market Size (2020-2031)
6.2 North America Next-Generation Gynecological Cancer Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2020-2025)
6.4 North America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Next-Generation Gynecological Cancer Diagnostics Market Size (2020-2031)
7.2 Europe Next-Generation Gynecological Cancer Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2020-2025)
7.4 Europe Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size (2020-2031)
8.2 Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size by Region (2020-2025)
8.4 Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Next-Generation Gynecological Cancer Diagnostics Market Size (2020-2031)
9.2 Latin America Next-Generation Gynecological Cancer Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2020-2025)
9.4 Latin America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size (2020-2031)
10.2 Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2020-2025)
10.4 Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Quest Diagnostics Incorporated
11.1.1 Quest Diagnostics Incorporated Company Details
11.1.2 Quest Diagnostics Incorporated Business Overview
11.1.3 Quest Diagnostics Incorporated Next-Generation Gynecological Cancer Diagnostics Introduction
11.1.4 Quest Diagnostics Incorporated Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.1.5 Quest Diagnostics Incorporated Recent Development
11.2 Thermo Fisher Scientific Inc.
11.2.1 Thermo Fisher Scientific Inc. Company Details
11.2.2 Thermo Fisher Scientific Inc. Business Overview
11.2.3 Thermo Fisher Scientific Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.2.4 Thermo Fisher Scientific Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.2.5 Thermo Fisher Scientific Inc. Recent Development
11.3 Agilent Technologies, Inc.
11.3.1 Agilent Technologies, Inc. Company Details
11.3.2 Agilent Technologies, Inc. Business Overview
11.3.3 Agilent Technologies, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.3.4 Agilent Technologies, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.3.5 Agilent Technologies, Inc. Recent Development
11.4 Invitae Corporation
11.4.1 Invitae Corporation Company Details
11.4.2 Invitae Corporation Business Overview
11.4.3 Invitae Corporation Next-Generation Gynecological Cancer Diagnostics Introduction
11.4.4 Invitae Corporation Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.4.5 Invitae Corporation Recent Development
11.5 Konica Minolta, Inc.
11.5.1 Konica Minolta, Inc. Company Details
11.5.2 Konica Minolta, Inc. Business Overview
11.5.3 Konica Minolta, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.5.4 Konica Minolta, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.5.5 Konica Minolta, Inc. Recent Development
11.6 BGI Genomics
11.6.1 BGI Genomics Company Details
11.6.2 BGI Genomics Business Overview
11.6.3 BGI Genomics Next-Generation Gynecological Cancer Diagnostics Introduction
11.6.4 BGI Genomics Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.6.5 BGI Genomics Recent Development
11.7 CENTOGENE N.V.
11.7.1 CENTOGENE N.V. Company Details
11.7.2 CENTOGENE N.V. Business Overview
11.7.3 CENTOGENE N.V. Next-Generation Gynecological Cancer Diagnostics Introduction
11.7.4 CENTOGENE N.V. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.7.5 CENTOGENE N.V. Recent Development
11.8 Fulgent Genetics, Inc.
11.8.1 Fulgent Genetics, Inc. Company Details
11.8.2 Fulgent Genetics, Inc. Business Overview
11.8.3 Fulgent Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.8.4 Fulgent Genetics, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.8.5 Fulgent Genetics, Inc. Recent Development
11.9 Illumina, Inc.
11.9.1 Illumina, Inc. Company Details
11.9.2 Illumina, Inc. Business Overview
11.9.3 Illumina, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.9.4 Illumina, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.9.5 Illumina, Inc. Recent Development
11.10 F. Hoffmann-La Roche Ltd
11.10.1 F. Hoffmann-La Roche Ltd Company Details
11.10.2 F. Hoffmann-La Roche Ltd Business Overview
11.10.3 F. Hoffmann-La Roche Ltd Next-Generation Gynecological Cancer Diagnostics Introduction
11.10.4 F. Hoffmann-La Roche Ltd Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.10.5 F. Hoffmann-La Roche Ltd Recent Development
11.11 Laboratory Corporation of America Holdings
11.11.1 Laboratory Corporation of America Holdings Company Details
11.11.2 Laboratory Corporation of America Holdings Business Overview
11.11.3 Laboratory Corporation of America Holdings Next-Generation Gynecological Cancer Diagnostics Introduction
11.11.4 Laboratory Corporation of America Holdings Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.11.5 Laboratory Corporation of America Holdings Recent Development
11.12 ARUP Laboratories
11.12.1 ARUP Laboratories Company Details
11.12.2 ARUP Laboratories Business Overview
11.12.3 ARUP Laboratories Next-Generation Gynecological Cancer Diagnostics Introduction
11.12.4 ARUP Laboratories Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.12.5 ARUP Laboratories Recent Development
11.13 Myriad Genetics, Inc.
11.13.1 Myriad Genetics, Inc. Company Details
11.13.2 Myriad Genetics, Inc. Business Overview
11.13.3 Myriad Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.13.4 Myriad Genetics, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.13.5 Myriad Genetics, Inc. Recent Development
11.14 OPKO Health, Inc.
11.14.1 OPKO Health, Inc. Company Details
11.14.2 OPKO Health, Inc. Business Overview
11.14.3 OPKO Health, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.14.4 OPKO Health, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.14.5 OPKO Health, Inc. Recent Development
11.15 QIAGEN N.V.
11.15.1 QIAGEN N.V. Company Details
11.15.2 QIAGEN N.V. Business Overview
11.15.3 QIAGEN N.V. Next-Generation Gynecological Cancer Diagnostics Introduction
11.15.4 QIAGEN N.V. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.15.5 QIAGEN N.V. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Ovarian Cancer Diagnosis
1.2.3 Cervical Cancer Diagnosis
1.2.4 Uterine Cancer Diagnosis
1.3 Market by Application
1.3.1 Global Next-Generation Gynecological Cancer Diagnostics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Next-Generation Gynecological Cancer Diagnostics Market Perspective (2020-2031)
2.2 Global Next-Generation Gynecological Cancer Diagnostics Growth Trends by Region
2.2.1 Global Next-Generation Gynecological Cancer Diagnostics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Next-Generation Gynecological Cancer Diagnostics Historic Market Size by Region (2020-2025)
2.2.3 Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Region (2026-2031)
2.3 Next-Generation Gynecological Cancer Diagnostics Market Dynamics
2.3.1 Next-Generation Gynecological Cancer Diagnostics Industry Trends
2.3.2 Next-Generation Gynecological Cancer Diagnostics Market Drivers
2.3.3 Next-Generation Gynecological Cancer Diagnostics Market Challenges
2.3.4 Next-Generation Gynecological Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Next-Generation Gynecological Cancer Diagnostics Players by Revenue
3.1.1 Global Top Next-Generation Gynecological Cancer Diagnostics Players by Revenue (2020-2025)
3.1.2 Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Players (2020-2025)
3.2 Global Next-Generation Gynecological Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Next-Generation Gynecological Cancer Diagnostics Revenue
3.4 Global Next-Generation Gynecological Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Next-Generation Gynecological Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next-Generation Gynecological Cancer Diagnostics Revenue in 2024
3.5 Global Key Players of Next-Generation Gynecological Cancer Diagnostics Head office and Area Served
3.6 Global Key Players of Next-Generation Gynecological Cancer Diagnostics, Product and Application
3.7 Global Key Players of Next-Generation Gynecological Cancer Diagnostics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Next-Generation Gynecological Cancer Diagnostics Breakdown Data by Type
4.1 Global Next-Generation Gynecological Cancer Diagnostics Historic Market Size by Type (2020-2025)
4.2 Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Type (2026-2031)
5 Next-Generation Gynecological Cancer Diagnostics Breakdown Data by Application
5.1 Global Next-Generation Gynecological Cancer Diagnostics Historic Market Size by Application (2020-2025)
5.2 Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Next-Generation Gynecological Cancer Diagnostics Market Size (2020-2031)
6.2 North America Next-Generation Gynecological Cancer Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2020-2025)
6.4 North America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Next-Generation Gynecological Cancer Diagnostics Market Size (2020-2031)
7.2 Europe Next-Generation Gynecological Cancer Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2020-2025)
7.4 Europe Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size (2020-2031)
8.2 Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size by Region (2020-2025)
8.4 Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Next-Generation Gynecological Cancer Diagnostics Market Size (2020-2031)
9.2 Latin America Next-Generation Gynecological Cancer Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2020-2025)
9.4 Latin America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size (2020-2031)
10.2 Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2020-2025)
10.4 Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Quest Diagnostics Incorporated
11.1.1 Quest Diagnostics Incorporated Company Details
11.1.2 Quest Diagnostics Incorporated Business Overview
11.1.3 Quest Diagnostics Incorporated Next-Generation Gynecological Cancer Diagnostics Introduction
11.1.4 Quest Diagnostics Incorporated Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.1.5 Quest Diagnostics Incorporated Recent Development
11.2 Thermo Fisher Scientific Inc.
11.2.1 Thermo Fisher Scientific Inc. Company Details
11.2.2 Thermo Fisher Scientific Inc. Business Overview
11.2.3 Thermo Fisher Scientific Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.2.4 Thermo Fisher Scientific Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.2.5 Thermo Fisher Scientific Inc. Recent Development
11.3 Agilent Technologies, Inc.
11.3.1 Agilent Technologies, Inc. Company Details
11.3.2 Agilent Technologies, Inc. Business Overview
11.3.3 Agilent Technologies, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.3.4 Agilent Technologies, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.3.5 Agilent Technologies, Inc. Recent Development
11.4 Invitae Corporation
11.4.1 Invitae Corporation Company Details
11.4.2 Invitae Corporation Business Overview
11.4.3 Invitae Corporation Next-Generation Gynecological Cancer Diagnostics Introduction
11.4.4 Invitae Corporation Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.4.5 Invitae Corporation Recent Development
11.5 Konica Minolta, Inc.
11.5.1 Konica Minolta, Inc. Company Details
11.5.2 Konica Minolta, Inc. Business Overview
11.5.3 Konica Minolta, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.5.4 Konica Minolta, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.5.5 Konica Minolta, Inc. Recent Development
11.6 BGI Genomics
11.6.1 BGI Genomics Company Details
11.6.2 BGI Genomics Business Overview
11.6.3 BGI Genomics Next-Generation Gynecological Cancer Diagnostics Introduction
11.6.4 BGI Genomics Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.6.5 BGI Genomics Recent Development
11.7 CENTOGENE N.V.
11.7.1 CENTOGENE N.V. Company Details
11.7.2 CENTOGENE N.V. Business Overview
11.7.3 CENTOGENE N.V. Next-Generation Gynecological Cancer Diagnostics Introduction
11.7.4 CENTOGENE N.V. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.7.5 CENTOGENE N.V. Recent Development
11.8 Fulgent Genetics, Inc.
11.8.1 Fulgent Genetics, Inc. Company Details
11.8.2 Fulgent Genetics, Inc. Business Overview
11.8.3 Fulgent Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.8.4 Fulgent Genetics, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.8.5 Fulgent Genetics, Inc. Recent Development
11.9 Illumina, Inc.
11.9.1 Illumina, Inc. Company Details
11.9.2 Illumina, Inc. Business Overview
11.9.3 Illumina, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.9.4 Illumina, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.9.5 Illumina, Inc. Recent Development
11.10 F. Hoffmann-La Roche Ltd
11.10.1 F. Hoffmann-La Roche Ltd Company Details
11.10.2 F. Hoffmann-La Roche Ltd Business Overview
11.10.3 F. Hoffmann-La Roche Ltd Next-Generation Gynecological Cancer Diagnostics Introduction
11.10.4 F. Hoffmann-La Roche Ltd Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.10.5 F. Hoffmann-La Roche Ltd Recent Development
11.11 Laboratory Corporation of America Holdings
11.11.1 Laboratory Corporation of America Holdings Company Details
11.11.2 Laboratory Corporation of America Holdings Business Overview
11.11.3 Laboratory Corporation of America Holdings Next-Generation Gynecological Cancer Diagnostics Introduction
11.11.4 Laboratory Corporation of America Holdings Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.11.5 Laboratory Corporation of America Holdings Recent Development
11.12 ARUP Laboratories
11.12.1 ARUP Laboratories Company Details
11.12.2 ARUP Laboratories Business Overview
11.12.3 ARUP Laboratories Next-Generation Gynecological Cancer Diagnostics Introduction
11.12.4 ARUP Laboratories Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.12.5 ARUP Laboratories Recent Development
11.13 Myriad Genetics, Inc.
11.13.1 Myriad Genetics, Inc. Company Details
11.13.2 Myriad Genetics, Inc. Business Overview
11.13.3 Myriad Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.13.4 Myriad Genetics, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.13.5 Myriad Genetics, Inc. Recent Development
11.14 OPKO Health, Inc.
11.14.1 OPKO Health, Inc. Company Details
11.14.2 OPKO Health, Inc. Business Overview
11.14.3 OPKO Health, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.14.4 OPKO Health, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.14.5 OPKO Health, Inc. Recent Development
11.15 QIAGEN N.V.
11.15.1 QIAGEN N.V. Company Details
11.15.2 QIAGEN N.V. Business Overview
11.15.3 QIAGEN N.V. Next-Generation Gynecological Cancer Diagnostics Introduction
11.15.4 QIAGEN N.V. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
11.15.5 QIAGEN N.V. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Ovarian Cancer Diagnosis
Table 3. Key Players of Cervical Cancer Diagnosis
Table 4. Key Players of Uterine Cancer Diagnosis
Table 5. Global Next-Generation Gynecological Cancer Diagnostics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Next-Generation Gynecological Cancer Diagnostics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Next-Generation Gynecological Cancer Diagnostics Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Region (2020-2025)
Table 9. Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Region (2026-2031)
Table 11. Next-Generation Gynecological Cancer Diagnostics Market Trends
Table 12. Next-Generation Gynecological Cancer Diagnostics Market Drivers
Table 13. Next-Generation Gynecological Cancer Diagnostics Market Challenges
Table 14. Next-Generation Gynecological Cancer Diagnostics Market Restraints
Table 15. Global Next-Generation Gynecological Cancer Diagnostics Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Players (2020-2025)
Table 17. Global Top Next-Generation Gynecological Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Gynecological Cancer Diagnostics as of 2024)
Table 18. Ranking of Global Top Next-Generation Gynecological Cancer Diagnostics Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Next-Generation Gynecological Cancer Diagnostics Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Next-Generation Gynecological Cancer Diagnostics, Headquarters and Area Served
Table 21. Global Key Players of Next-Generation Gynecological Cancer Diagnostics, Product and Application
Table 22. Global Key Players of Next-Generation Gynecological Cancer Diagnostics, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Next-Generation Gynecological Cancer Diagnostics Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Type (2020-2025)
Table 26. Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Type (2026-2031)
Table 28. Global Next-Generation Gynecological Cancer Diagnostics Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Application (2020-2025)
Table 30. Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Application (2026-2031)
Table 32. North America Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2026-2031) & (US$ Million)
Table 47. Quest Diagnostics Incorporated Company Details
Table 48. Quest Diagnostics Incorporated Business Overview
Table 49. Quest Diagnostics Incorporated Next-Generation Gynecological Cancer Diagnostics Product
Table 50. Quest Diagnostics Incorporated Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 51. Quest Diagnostics Incorporated Recent Development
Table 52. Thermo Fisher Scientific Inc. Company Details
Table 53. Thermo Fisher Scientific Inc. Business Overview
Table 54. Thermo Fisher Scientific Inc. Next-Generation Gynecological Cancer Diagnostics Product
Table 55. Thermo Fisher Scientific Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 56. Thermo Fisher Scientific Inc. Recent Development
Table 57. Agilent Technologies, Inc. Company Details
Table 58. Agilent Technologies, Inc. Business Overview
Table 59. Agilent Technologies, Inc. Next-Generation Gynecological Cancer Diagnostics Product
Table 60. Agilent Technologies, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 61. Agilent Technologies, Inc. Recent Development
Table 62. Invitae Corporation Company Details
Table 63. Invitae Corporation Business Overview
Table 64. Invitae Corporation Next-Generation Gynecological Cancer Diagnostics Product
Table 65. Invitae Corporation Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 66. Invitae Corporation Recent Development
Table 67. Konica Minolta, Inc. Company Details
Table 68. Konica Minolta, Inc. Business Overview
Table 69. Konica Minolta, Inc. Next-Generation Gynecological Cancer Diagnostics Product
Table 70. Konica Minolta, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 71. Konica Minolta, Inc. Recent Development
Table 72. BGI Genomics Company Details
Table 73. BGI Genomics Business Overview
Table 74. BGI Genomics Next-Generation Gynecological Cancer Diagnostics Product
Table 75. BGI Genomics Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 76. BGI Genomics Recent Development
Table 77. CENTOGENE N.V. Company Details
Table 78. CENTOGENE N.V. Business Overview
Table 79. CENTOGENE N.V. Next-Generation Gynecological Cancer Diagnostics Product
Table 80. CENTOGENE N.V. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 81. CENTOGENE N.V. Recent Development
Table 82. Fulgent Genetics, Inc. Company Details
Table 83. Fulgent Genetics, Inc. Business Overview
Table 84. Fulgent Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Product
Table 85. Fulgent Genetics, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 86. Fulgent Genetics, Inc. Recent Development
Table 87. Illumina, Inc. Company Details
Table 88. Illumina, Inc. Business Overview
Table 89. Illumina, Inc. Next-Generation Gynecological Cancer Diagnostics Product
Table 90. Illumina, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 91. Illumina, Inc. Recent Development
Table 92. F. Hoffmann-La Roche Ltd Company Details
Table 93. F. Hoffmann-La Roche Ltd Business Overview
Table 94. F. Hoffmann-La Roche Ltd Next-Generation Gynecological Cancer Diagnostics Product
Table 95. F. Hoffmann-La Roche Ltd Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 96. F. Hoffmann-La Roche Ltd Recent Development
Table 97. Laboratory Corporation of America Holdings Company Details
Table 98. Laboratory Corporation of America Holdings Business Overview
Table 99. Laboratory Corporation of America Holdings Next-Generation Gynecological Cancer Diagnostics Product
Table 100. Laboratory Corporation of America Holdings Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 101. Laboratory Corporation of America Holdings Recent Development
Table 102. ARUP Laboratories Company Details
Table 103. ARUP Laboratories Business Overview
Table 104. ARUP Laboratories Next-Generation Gynecological Cancer Diagnostics Product
Table 105. ARUP Laboratories Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 106. ARUP Laboratories Recent Development
Table 107. Myriad Genetics, Inc. Company Details
Table 108. Myriad Genetics, Inc. Business Overview
Table 109. Myriad Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Product
Table 110. Myriad Genetics, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 111. Myriad Genetics, Inc. Recent Development
Table 112. OPKO Health, Inc. Company Details
Table 113. OPKO Health, Inc. Business Overview
Table 114. OPKO Health, Inc. Next-Generation Gynecological Cancer Diagnostics Product
Table 115. OPKO Health, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 116. OPKO Health, Inc. Recent Development
Table 117. QIAGEN N.V. Company Details
Table 118. QIAGEN N.V. Business Overview
Table 119. QIAGEN N.V. Next-Generation Gynecological Cancer Diagnostics Product
Table 120. QIAGEN N.V. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 121. QIAGEN N.V. Recent Development
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
Table 125. Authors List of This Report
List of Figures
Figure 1. Next-Generation Gynecological Cancer Diagnostics Picture
Figure 2. Global Next-Generation Gynecological Cancer Diagnostics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Type: 2024 VS 2031
Figure 4. Ovarian Cancer Diagnosis Features
Figure 5. Cervical Cancer Diagnosis Features
Figure 6. Uterine Cancer Diagnosis Features
Figure 7. Global Next-Generation Gynecological Cancer Diagnostics Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Application: 2024 VS 2031
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Others Case Studies
Figure 12. Next-Generation Gynecological Cancer Diagnostics Report Years Considered
Figure 13. Global Next-Generation Gynecological Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Next-Generation Gynecological Cancer Diagnostics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Region: 2024 VS 2031
Figure 16. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Players in 2024
Figure 17. Global Top Next-Generation Gynecological Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Gynecological Cancer Diagnostics as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Next-Generation Gynecological Cancer Diagnostics Revenue in 2024
Figure 19. North America Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Next-Generation Gynecological Cancer Diagnostics Market Share by Country (2020-2031)
Figure 21. United States Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Next-Generation Gynecological Cancer Diagnostics Market Share by Country (2020-2031)
Figure 25. Germany Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Share by Region (2020-2031)
Figure 33. China Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Next-Generation Gynecological Cancer Diagnostics Market Share by Country (2020-2031)
Figure 41. Mexico Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Share by Country (2020-2031)
Figure 45. Turkey Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Quest Diagnostics Incorporated Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 49. Thermo Fisher Scientific Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 50. Agilent Technologies, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 51. Invitae Corporation Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 52. Konica Minolta, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 53. BGI Genomics Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 54. CENTOGENE N.V. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 55. Fulgent Genetics, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 56. Illumina, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 57. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 58. Laboratory Corporation of America Holdings Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 59. ARUP Laboratories Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 60. Myriad Genetics, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 61. OPKO Health, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 62. QIAGEN N.V. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Table 1. Global Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Ovarian Cancer Diagnosis
Table 3. Key Players of Cervical Cancer Diagnosis
Table 4. Key Players of Uterine Cancer Diagnosis
Table 5. Global Next-Generation Gynecological Cancer Diagnostics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Next-Generation Gynecological Cancer Diagnostics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Next-Generation Gynecological Cancer Diagnostics Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Region (2020-2025)
Table 9. Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Region (2026-2031)
Table 11. Next-Generation Gynecological Cancer Diagnostics Market Trends
Table 12. Next-Generation Gynecological Cancer Diagnostics Market Drivers
Table 13. Next-Generation Gynecological Cancer Diagnostics Market Challenges
Table 14. Next-Generation Gynecological Cancer Diagnostics Market Restraints
Table 15. Global Next-Generation Gynecological Cancer Diagnostics Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Players (2020-2025)
Table 17. Global Top Next-Generation Gynecological Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Gynecological Cancer Diagnostics as of 2024)
Table 18. Ranking of Global Top Next-Generation Gynecological Cancer Diagnostics Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Next-Generation Gynecological Cancer Diagnostics Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Next-Generation Gynecological Cancer Diagnostics, Headquarters and Area Served
Table 21. Global Key Players of Next-Generation Gynecological Cancer Diagnostics, Product and Application
Table 22. Global Key Players of Next-Generation Gynecological Cancer Diagnostics, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Next-Generation Gynecological Cancer Diagnostics Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Type (2020-2025)
Table 26. Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Type (2026-2031)
Table 28. Global Next-Generation Gynecological Cancer Diagnostics Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Application (2020-2025)
Table 30. Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Application (2026-2031)
Table 32. North America Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2026-2031) & (US$ Million)
Table 47. Quest Diagnostics Incorporated Company Details
Table 48. Quest Diagnostics Incorporated Business Overview
Table 49. Quest Diagnostics Incorporated Next-Generation Gynecological Cancer Diagnostics Product
Table 50. Quest Diagnostics Incorporated Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 51. Quest Diagnostics Incorporated Recent Development
Table 52. Thermo Fisher Scientific Inc. Company Details
Table 53. Thermo Fisher Scientific Inc. Business Overview
Table 54. Thermo Fisher Scientific Inc. Next-Generation Gynecological Cancer Diagnostics Product
Table 55. Thermo Fisher Scientific Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 56. Thermo Fisher Scientific Inc. Recent Development
Table 57. Agilent Technologies, Inc. Company Details
Table 58. Agilent Technologies, Inc. Business Overview
Table 59. Agilent Technologies, Inc. Next-Generation Gynecological Cancer Diagnostics Product
Table 60. Agilent Technologies, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 61. Agilent Technologies, Inc. Recent Development
Table 62. Invitae Corporation Company Details
Table 63. Invitae Corporation Business Overview
Table 64. Invitae Corporation Next-Generation Gynecological Cancer Diagnostics Product
Table 65. Invitae Corporation Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 66. Invitae Corporation Recent Development
Table 67. Konica Minolta, Inc. Company Details
Table 68. Konica Minolta, Inc. Business Overview
Table 69. Konica Minolta, Inc. Next-Generation Gynecological Cancer Diagnostics Product
Table 70. Konica Minolta, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 71. Konica Minolta, Inc. Recent Development
Table 72. BGI Genomics Company Details
Table 73. BGI Genomics Business Overview
Table 74. BGI Genomics Next-Generation Gynecological Cancer Diagnostics Product
Table 75. BGI Genomics Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 76. BGI Genomics Recent Development
Table 77. CENTOGENE N.V. Company Details
Table 78. CENTOGENE N.V. Business Overview
Table 79. CENTOGENE N.V. Next-Generation Gynecological Cancer Diagnostics Product
Table 80. CENTOGENE N.V. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 81. CENTOGENE N.V. Recent Development
Table 82. Fulgent Genetics, Inc. Company Details
Table 83. Fulgent Genetics, Inc. Business Overview
Table 84. Fulgent Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Product
Table 85. Fulgent Genetics, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 86. Fulgent Genetics, Inc. Recent Development
Table 87. Illumina, Inc. Company Details
Table 88. Illumina, Inc. Business Overview
Table 89. Illumina, Inc. Next-Generation Gynecological Cancer Diagnostics Product
Table 90. Illumina, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 91. Illumina, Inc. Recent Development
Table 92. F. Hoffmann-La Roche Ltd Company Details
Table 93. F. Hoffmann-La Roche Ltd Business Overview
Table 94. F. Hoffmann-La Roche Ltd Next-Generation Gynecological Cancer Diagnostics Product
Table 95. F. Hoffmann-La Roche Ltd Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 96. F. Hoffmann-La Roche Ltd Recent Development
Table 97. Laboratory Corporation of America Holdings Company Details
Table 98. Laboratory Corporation of America Holdings Business Overview
Table 99. Laboratory Corporation of America Holdings Next-Generation Gynecological Cancer Diagnostics Product
Table 100. Laboratory Corporation of America Holdings Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 101. Laboratory Corporation of America Holdings Recent Development
Table 102. ARUP Laboratories Company Details
Table 103. ARUP Laboratories Business Overview
Table 104. ARUP Laboratories Next-Generation Gynecological Cancer Diagnostics Product
Table 105. ARUP Laboratories Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 106. ARUP Laboratories Recent Development
Table 107. Myriad Genetics, Inc. Company Details
Table 108. Myriad Genetics, Inc. Business Overview
Table 109. Myriad Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Product
Table 110. Myriad Genetics, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 111. Myriad Genetics, Inc. Recent Development
Table 112. OPKO Health, Inc. Company Details
Table 113. OPKO Health, Inc. Business Overview
Table 114. OPKO Health, Inc. Next-Generation Gynecological Cancer Diagnostics Product
Table 115. OPKO Health, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 116. OPKO Health, Inc. Recent Development
Table 117. QIAGEN N.V. Company Details
Table 118. QIAGEN N.V. Business Overview
Table 119. QIAGEN N.V. Next-Generation Gynecological Cancer Diagnostics Product
Table 120. QIAGEN N.V. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025) & (US$ Million)
Table 121. QIAGEN N.V. Recent Development
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
Table 125. Authors List of This Report
List of Figures
Figure 1. Next-Generation Gynecological Cancer Diagnostics Picture
Figure 2. Global Next-Generation Gynecological Cancer Diagnostics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Type: 2024 VS 2031
Figure 4. Ovarian Cancer Diagnosis Features
Figure 5. Cervical Cancer Diagnosis Features
Figure 6. Uterine Cancer Diagnosis Features
Figure 7. Global Next-Generation Gynecological Cancer Diagnostics Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Application: 2024 VS 2031
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Others Case Studies
Figure 12. Next-Generation Gynecological Cancer Diagnostics Report Years Considered
Figure 13. Global Next-Generation Gynecological Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Next-Generation Gynecological Cancer Diagnostics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Region: 2024 VS 2031
Figure 16. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Players in 2024
Figure 17. Global Top Next-Generation Gynecological Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Gynecological Cancer Diagnostics as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Next-Generation Gynecological Cancer Diagnostics Revenue in 2024
Figure 19. North America Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Next-Generation Gynecological Cancer Diagnostics Market Share by Country (2020-2031)
Figure 21. United States Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Next-Generation Gynecological Cancer Diagnostics Market Share by Country (2020-2031)
Figure 25. Germany Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Share by Region (2020-2031)
Figure 33. China Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Next-Generation Gynecological Cancer Diagnostics Market Share by Country (2020-2031)
Figure 41. Mexico Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Share by Country (2020-2031)
Figure 45. Turkey Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Quest Diagnostics Incorporated Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 49. Thermo Fisher Scientific Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 50. Agilent Technologies, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 51. Invitae Corporation Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 52. Konica Minolta, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 53. BGI Genomics Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 54. CENTOGENE N.V. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 55. Fulgent Genetics, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 56. Illumina, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 57. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 58. Laboratory Corporation of America Holdings Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 59. ARUP Laboratories Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 60. Myriad Genetics, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 61. OPKO Health, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 62. QIAGEN N.V. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2020-2025)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Household Embroidery Machines Market Research Report 2025
Jul 18, 25
Global Residential Electric Underfloor Heating Market Research Report 2025
Jul 18, 25
Global Commercial Electric Underfloor Heating Market Research Report 2025
Jul 18, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232